Evidence map›Paper›PMID 36308366›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2022

Full Compliance of Adjuvant Endocrine Therapy Is Associated with Higher Disease-Free Survival in Hormone Receptor-Positive and HER2-Negative Chinese Breast Cancer Patients with First Tumor Recurrence.

Zhensheng Li, Yunjiang Liu, Yue Li, Yuguang Shang, Kaiye Du, Xiaohui Ji, Huina Han, Jun Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Zhensheng LiDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yunjiang LiuDepartment of Breast Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yue LiDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yuguang ShangDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Kaiye DuDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xiaohui JiDepartment of Ultrasound, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Huina HanDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jun ZhangDepartment of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo characterize the compliance status of adjuvant endocrine therapy (aET) and its relationship with disease-free survival (DFS) in hormone receptor-positive (HR+) and HER2-negative (HER2-) in Chinese breast cancer (BC) patients with first tumor recurrence.

methodsAll women with primary unilateral stage I - III HR+HER2- BC and first tumor recurrence in 2008 - 2018 at our institution were identified. Full (vs. none/partial) compliance of aET was classified from records. Multivariate Cox regression estimated the hazard ratio (HR), its 95% confidence interval (CI), and p value. DFS. Covariates included age, T stage, N stage, pathology, tumor grade, LVI, chemotherapy, radiotherapy.      Results: A total 258 patients had average age 47.4 years at BC diagnosis and median DFS 31.7 months. Patients with ipsilateral (contralateral) region and organ recurrence were 47.7% (19.8%) and 71.9%. Compared to the patients with none/partial compliance of aET, the full compliance patients (54.3% ) had a higher DFS (median 35.0 vs. 25.2 months, p=0.009). Multivariate analysis showed that the full compliance of aET was associated with a lower HR 0.614 (95%CI 0.467 - 0.807, p<0.001) on recurrence. Early discontinuation (67.5%, 56/83) due to the drug side effects was the top reason for partial compliance of aET.

conclusionsFull compliance of aET was quite low in Chinese HR+HER2- BC patients. However, it was associated with a 38.6% lower risk of first tumor recurrence. To search for effective tools to improve the compliance of aET in this population should be stressed.

Indexed as

Breast NeoplasmsChemotherapy, AdjuvantChinaDisease-Free SurvivalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoplasm Recurrence, LocalErb-b2 Receptor Tyrosine Kinasesbreast cancerdisease-free survivalDrug complianceendocrine therapyHormone receptor-positive

Identifiers

PMID36308366
PMCPMC9924327
OpenAlexW4307808793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.